BioPharmSignal logoBioPharmSignal

Biotech News

Assembly Biosciences to Participate in Upcoming Investor Conferences

Assembly Biosciences (ASMB)Assembly BiosciencesCompany update

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present and participate in one-on-one meetings at

Related news

ASMBAssembly Biosciences2026-05-28 20:05 EST

Assembly Biosciences Announces Upcoming Investor Conference Presentations

ASMBAssembly Biosciences2026-10-29 20:00 EST

Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus

ENTAEnanta Pharmaceuticals2026-11-04 12:00 EST

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences

ANTXAN2 Therapeutics2026-10-20 20:13 EST

AN2 Therapeutics to Participate at Upcoming Investor Conferences

IMNNImunon2026-10-08 13:00 EST

IMUNON to Participate in Upcoming Investor Conferences

SCYXSCYNEXIS2026-09-01 12:30 EST

SCYNEXIS to Participate in Upcoming Investor Conferences

ENTAEnanta Pharmaceuticals2026-09-01 11:00 EST

Enanta Pharmaceuticals to Participate in September Investor Conferences

SPROSpero Therapeutics2026-11-02 22:05 EST

Spero Therapeutics to Present at Investor Conferences in November

SCYXSCYNEXIS2026-10-29 12:00 EST

SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference

SPROSpero Therapeutics2026-10-15 21:05 EST

Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare Conference

View all latest news

Assembly Biosciences

Antiviral Small Molecules Assembly Biosciences develops oral small-molecule therapies for serious viral diseases. Its portfolio targets viral replication mechanisms with the goal of improving suppression or enabling finite treatment. Recurrent Genital Herpes ABI-5366 and ABI-1179 are helicase-primase inhibitors that have completed Phase...

Recent company news

ASMBAssembly Biosciences2026-11-02 21:00 EST

Assembly Biosciences to Participate in Upcoming Investor Conferences

ASMBAssembly Biosciences2026-10-29 20:00 EST

Assembly Biosciences Doses First Two Participants in Phase 2 Study of Oral NTCP Inhibitor ABI-6250 for Chronic Hepatitis Delta Virus

ASMBAssembly Biosciences2026-10-05 14:00 EST

Assembly Biosciences to Present Positive Phase 1a Safety, Tolerability and Target Engagement Data for ABI-6250 at AASLD The Liver Meeting® 2026

ASMBAssembly Biosciences2026-09-10 20:15 EST

Assembly Biosciences to Present at the H.C. Wainwright & Co. 28th Annual Global Investment Conference

ASMBAssembly Biosciences2026-09-08 20:00 EST

Assembly Biosciences Exercises U.S. Profit-Share Option with Gilead for HSV Helicase-Primase Inhibitor Program

Stock data

Close
20.00 USD
Market cap
485.32M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States